athma
Conditions
Interventions
Ultra fine beclomethasone/formoterol group:Inhalation therapy
Budesonide/formoterol group:Inhalation therapy
Sponsors
Beijing Medical and Health Public Welfare Foundation
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65 years old; 2. Clinical asthma diagnosis confirmed by a respiratory specialist according to GINA 2024 and meets any of the following conditions: positive chlormecholine provocation test; Positive bronchodilation test (FEV1 increases by at least 12% from baseline FEV1 and >=200 mL after inhalation of 400 µg albuterol by pressurized metered-dose inhaler); or peak expiratory flow variability measured over a 7-day period of more than 20%; Maintenance of anti-asthmatic therapy cycles (eg, 4 weeks) has documented reversibility. 3. Smoking for less than 10 years
Exclusion criteria
Exclusion criteria: Chronic obstructive pulmonary disease, malignant tumors, chronic renal insufficiency, chronic heart insufficiency, chronic liver disease, conflicting with other studies included in this study, and refusing to sign the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lung function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cough VAS Score;Asthma Control Test Score,ACT Score;Medication Adherence Report Scale,MARS-5;FeNO;Absolute Eosinophil Count;C-reactive protein; | — |
Countries
China
Contacts
Public ContactJinxiang Wang
Research leader
Outcome results
None listed